Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia Patients
Authors:
- 28 July 2018
- journal article
- research article
- Published by Springer Nature in Neurotoxicity Research
- Vol. 35 (1) , 122-138
Abstract
Eotaxin is increased in neurodegenerative disorders and schizophrenia, and preclinical studies indicate that eotaxin may induce cognitive deficits. This study aims to examine whether peripheral levels of eotaxin impact cognitive functioning in healthy volunteers and formal thought disorder (FTD) and psychopathology in schizophrenia patients. Serum levels of eotaxin were assayed and cognitive tests were performed on a sample of 40 healthy participants and 80 schizophrenia patients. Among healthy participants, eotaxin levels were significantly associated with episodic/semantic memory, executive functions, Mini Mental State Examination, emotion recognition, and sustained attention. In addition, age-related effects on these cognitive measures were partly mediated by eotaxin. The super-variable “age-eotaxin” predicted a large part of the variance in cognitive functions among healthy participants, and hence, eotaxin may act as an “accelerated brain aging chemokine” (ABAC). In schizophrenia, eotaxin levels had a strong impact on formal thought disorders and psychopathology. In schizophrenia, increased eotaxin strongly impacts memory and sustained attention, which together to a large extent determine FTD. FTD together with memory deficits predicts around 92.5% of the variance in psychopathology. Moreover, the effects of eotaxin are partially mediated by executive functioning, while the effects of male sex on FTD and psychopathology are mediated by eotaxin. In healthy subjects, eotaxin strongly impacts executive functioning and multiple cognitive domains. In schizophrenia, peripheral levels of eotaxin strongly impact both negative symptoms and psychosis (hallucinations and delusions), and these eotaxin effects are mediated by impairments in frontal functioning, memory, sustained attention, and FTD. Eotaxin is an endogenous cognitive deteriorating chemokine (ECDC) and a novel therapeutic target for age-related cognitive decline and schizophrenia as well.Keywords
Funding Information
- Asahi Glass Foundation (NA)
- Ratchadapiseksompotch Fund, (RA60/042)
This publication has 61 references indexed in Scilit:
- Executive Functioning in SchizophreniaFrontiers in Psychiatry, 2013
- Expression of Ccl11 Associates with Immune Response Modulation and Protection against Neuroinflammation in RatsPLOS ONE, 2012
- The ageing systemic milieu negatively regulates neurogenesis and cognitive functionNature, 2011
- The role of sex hormones in the development of Th2 immunity in a gender‐biased model of Trichuris muris infectionEuropean Journal of Immunology, 2010
- Effects of facial nerve axotomy on Th2- and Th1-associated chemokine expression in the facial motor nucleus of wild-type and presymptomatic mSOD1 miceJournal of Neuroimmunology, 2009
- Chemokines as modulators of neuroendocrine functionsJournal of Molecular Endocrinology, 2007
- Negative Symptoms and Cognitive Deficits: What Is the Nature of Their Relationship?Schizophrenia Bulletin, 2005
- Working Memory Maintenance Contributes to Long-term Memory Formation: Neural and Behavioral EvidenceJournal of Cognitive Neuroscience, 2005
- IL-13 induces eosinophil recruitment into the lung by an IL-5– and eotaxin-dependent mechanismJournal of Allergy and Clinical Immunology, 2001
- Schizophrenic syndromes, cognitive performance and neurological dysfunctionPsychological Medicine, 1987